All In Biotech

Free tool

FAERS Monitor: Avsola

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming BLA 761086 or its brand name (Avsola, Infliximab-Axxq). Reports on generic versions are filed under their own applications.

Reports

1,160

Serious

668

58% of reports

Hospitalization

266

Death reported

79

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • off label use331
  • product storage error143
  • circumstance or information capable of leading to medication error99
  • drug ineffective89
  • fatigue87
  • dyspnoea79
  • infusion related reaction71
  • diarrhoea70
  • arthralgia69
  • pain68
  • crohn^s disease67
  • nausea61
  • rash61
  • headache60
  • pneumonia60

Reports by year received

View as table
YearReports
202016
202184
2022130
2023214
2024213
2025139
2026364

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,052,999 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

FDA's data service returned an error (400). The numbers below may be missing or incomplete.
ReactionReportsPRR95% CI lowerChi-squared
circumstance or information capable of leading to medication errorSignal9953.344.15,022
product storage errorSignal14329.725.43,942
infusion related reactionSignal7119.415.51,226
off label useSignal3316.96.31,721
pneumoniaSignal603.42.699
arthralgiaSignal693.02.492
rashSignal612.52.056
dyspnoeaSignal792.52.074
fatigueSignal872.01.746
painSignal682.01.634
diarrhoea702.01.633
headache601.71.419
nausea611.41.17
drug ineffective891.21.04
crohn^s disease670.00.01,197,914

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.